

Stocks That Could Double in 2022

For months, we've dealt with absolute chaos in the markets.

There was the coronavirus, the geopolitical issues, inflation, fears of Fed action, depressing economic outlooks, you name it...Now, investors want to know what's going to happen next.

Unfortunately, we can't tell you that with 100% certainty. Our crystal ball is in the shop.

But we can point you in the direction of red hot stocks that could double in the New Year.

Lithium Americas (LAC)

At \$27 a share, Lithium Americas could easily see higher highs.

All thanks to a lithium bull market that shows no signs of slowing – at least not soon. For one, by 2030, 125 million electric vehicles could be on the road. Two, major automakers are starting to abandon internal combustion engines for EVs.

However, for millions of EVs to hit the roads, each will need around 22 pounds of lithium.

Unfortunately, the world is in short supply, with massive demand.

Even the International Energy Agency is warning that the, "The supply of critical minerals crucial for technologies such as wind turbines and electric vehicles will have to be ramped up over the next decades if the planet's climate targets are to be met."

That's a strong catalyst for Lithium Americas.

Even better, construction activities at Caucharí-Olaroz remain on track to achieve first production by mid-2022 on the initial 40,000 tonnes per annum operation.

At Thacker Pass, results of a Feasibility Study on the first phase of Thacker Pass (for at least 30,000-35,000 tpa of lithium carbonate) are expected by year end. Engineering is underway to consider a 20,000 tpa lithium hydroxide chemical conversion plant, to provide flexibility to meet potential customer and partner needs.

Affirm Holdings (AFRM)

At \$78, Affirm Holdings could still double in the New Year.

For one, according to Barron's, "BNPL is gaining popularity given that interest rates are ultralow, reducing costs for consumers. Other fintech apps have entered the market, including Affirm, a pure play on the sector, and PayPal (PYPL). Apple (AAPL) is also developing a BNPL service with Goldman Sachs Group (GS), its credit-card partner."

Two, BNPL has some major players coming in. PayPal for example just bought BNPL company Paidy for \$2.7 billion. Square just bought Afterpay for \$29 billion.

Three, momentum shows no signs of slowing.

For one, AFRM has major partnerships with companies, like Amazon and Target.

In fact, Affirm just expanded its relationship with Amazon. "Affirm will be a financing option for all eligible purchases of \$50 or more on Amazon.com and the Amazon mobile app. The company said Affirm will be the only third-party, non-credit-card buy now, pay later option for U.S. Amazon customers," says Barron's.

Cassava Sciences (SAVA)

Cassava Sciences could be one of the most talked about Alzheimer's stocks of 2022.

Despite all of the negativity, Cassava pushed forward with Phase III trials.

In October, the company announced it initiated a Phase 3 efficacy study of simufilam, the Company's investigational drug for patients with Alzheimer's disease, with a second Phase 3 efficacy study of simufilam in Alzheimer's disease is expected to begin by year end.

Shortly after, SAVA would explode higher.

All after a review by the Journal of Neuroscience showed no evidence of data manipulation with the company's drug candidate.

"The Journal of Neuroscience follows COPE [Committee on Publication Ethics] guidelines and takes any claims of misconduct very seriously. In response to allegations of data manipulation in JNeurosci 2012;32:9773-9784 the Journal requested raw data, including images of original, uncropped Western blots. The Journal determined that there was one duplicated panel in Figure 8 and a Corrigendum was requested and will be printed. No evidence of data manipulation was found for Western blot data," as noted in a SAVA press release.

Should Phase 3 results be as impressive as prior reports, SAVA could easily race back to \$120. Especially if it can successfully help millions of people with mild to moderate Alzheimer's.

Cassava Sciences' Phase 3 efficacy studies of simufilam in Alzheimer's disease are being conducted under Special Protocol Assessments (SPA) from the U.S. Food and Drug Administration (FDA). The SPAs document that FDA has reviewed and agreed upon the key design features of Cassava Sciences' Phase 3 study protocols.